Pakistan's drug watchdog has approved phase-III clinical trial of a COVID-19 vaccine developed in collaboration with a Chinese company, reports said on Tuesday. The NIH said this would be the first-ever phase-III clinical trial for any vaccine in Pakistan. "It is a multi-country multi-centre clinical trial which CanSinoBio is already conducting in China, Russia, Chile, Argentina and will shortly start in Saudi Arabia. The principal investigator of the multi-centre clinical trial in Pakistan is NIH executive director Maj Gen Aamer Ikram," the NIH said. "AJM Pharma CEO Adnan Hussain signed an agreement with the NIH last month for collaborating on the phase-III clinical trial of CanSinoBIO Ad5-nCoV in Pakistan," the statement said.

Source: dna August 18, 2020 15:33 UTC